The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Eisai Limited4 个研究点分布在 2 个国家开始时间: 2002年8月最近更新: 2013年5月10日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Eisai Limited
试验地点: 4
主要终点: PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 40 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

PD patients with dementia will be screened up to 4 weeks prior to initiating dose administration. Baseline measurement on efficacy measures will be conducted at baseline, after which the first dose of study medication will be administered.

次要结局

未报告次要终点

研究者

发起方

Eisai Limited

申办方类型

Industry

研究点 (4)

Loading locations...

相似试验

已完成

3 期

Phase 3 Randomized Placebo Controlled Clinical Trial of DonepezilCognitive DysfunctionMemory Impairment

NCT02822573Wake Forest University Health Sciences276

终止

3 期

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10Down SyndromeCognitive Dysfunction

NCT00754013Eisai Inc.9

终止

3 期

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17Down SyndromeCognitive Dysfunction

NCT00754052Eisai Inc.8

已完成

3 期

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)Behavioral SymptomsAutistic Disorder

NCT00337571Otsuka Pharmaceutical Development & Commercialization, Inc.218

已完成

3 期

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).Autistic Disorder

NCT00332241Otsuka Pharmaceutical Development & Commercialization, Inc.98